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Abstract 
Guanylate cyclase C (GUCY2C) is a tumor suppressing receptor silenced by loss of expression of 
its luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This 
observation suggests oral replacement with a GUCY2C agonist may be an effective targeted 
chemoprevention agent.  Linaclotide is an FDA approved oral GUCY2C agonist formulated for 
gastric release, inducing fluid secretion into the small bowel to treat chronic idiopathic 
constipation. The ability of oral linaclotide to induce a pharmacodynamic response in epithelial 
cells of the colorectum in humans remains undefined. Here, we demonstrate that 
administration of 0.87 milligrams of oral linaclotide daily for 7 days to healthy volunteers, after 
oral colon preparation with polyethylene glycol solution (MoviPrep), activates GUCY2C, 
resulting in accumulation of its product cyclic (c)GMP in epithelial cells of the cecum, transverse 
colon, and distal rectum. GUCY2C activation by oral linaclotide was associated with homeostatic 
signaling, including phosphorylation of vasodilator-stimulated phosphoprotein and inhibition of 
proliferation quantified by reduced Ki67-positive epithelial cells. In the absence of the complete 
oral colonoscopy preparation, linaclotide did not alter cGMP production in epithelial cells of the 
colorectum, demonstrating that there was an effect related to the laxative preparation. These 
data show that the current FDA-approved formulation of oral linaclotide developed for small 
bowel delivery to treat chronic idiopathic constipation is inadequate for reliably regulating 
GUCY2C in the colorectum to prevent tumorigenesis. The study results highlight the importance 
of developing a novel GUCY2C agonist formulated for release and activity targeted to the large 
intestine for colorectal cancer prevention.  
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Introduction 
Colorectal cancer is the 4th most commonly diagnosed cancer in the United States, with 
approximately 150,000 new cases recorded each year.(1)  Over the course of a lifetime, about 1 
in 20 U.S. residents will be diagnosed with this disease. Despite advances in early detection and 
treatment, the mortality rate for colorectal cancer remains nearly 50%.  Although screening and 
surveillance continue to be the cornerstone of colorectal cancer prevention, chemoprevention 
has emerged as a complementary approach among higher risk participants.  To date, aspirin 
(ASA) and other nonsteroidal anti-inflammatory drugs (NSAIDs) represent the most thoroughly 
investigated class of colorectal cancer chemoprevention agents.  However, given the 
established risk/benefit profile of these agents, the widespread use of ASA or other NSAIDs 
strictly for colorectal cancer chemoprevention seems unlikely in the average-risk population. 
Guanylate cyclase C (GUCY2C) is the intestinal epithelial cell receptor (2) for the endogenous 
hormones guanylin and uroguanylin.  Hormone-receptor interaction activates the intracellular 
catalytic domain, which converts guanosine triphosphate to cyclic guanosine monophosphate 
(cGMP).  This cyclic nucleotide activates signaling intermediates, including cGMP-dependent 
protein kinase (PKG), which phosphorylates downstream effectors including vasodilator-
stimulated phosphoprotein (VASP) and cystic fibrosis transmembrane conductance regulator 
(CFTR).  Phosphorylation of CFTR opens this chloride channel, resulting in fluid and electrolyte 
secretion.  This mechanism has been co-opted by bacteria that secrete heat-stable enterotoxins 
(STs), which are structural and functional homologs of guanylin and uroguanylin, to induce 
GUCY2C-dependent diarrhea.(3-5)  Beyond secretion, GUCY2C and its ligands also regulate 
intestinal homeostasis along the crypt-villus axis by restricting proliferative dynamics and 
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coordinating cell cycle, differentiation, and metabolic circuits.(6-8)  In that context, guanylin 
and uroguanylin are the most commonly lost gene products in colorectal cancer in animals and 
humans.(9-11)  Of significance, epithelial cells undergoing transformation continue to express 
GUCY2C.  Indeed, colon cancer cells over-express GUCY2C compared to normal adjacent 
mucosa.(12, 13)  Moreover, we have previously demonstrated that pharmacologic or genetic 
delivery of GUCY2C ligands opposes intestinal tumorigenesis in mice.(14, 15) 
Taken together, these data support that GUCY2C is a tumor suppressing receptor when 
silenced, due to the loss of expression of guanylin and uroguanylin, universally contributes to 
early development of colorectal cancer.  These properties highlight the potential value of oral 
replacement with GUCY2C agonists as targeted prevention for colorectal cancer.  Oral GUCY2C 
agonists have impressive safety profiles in pre-clinical through late-stage clinical trials for the 
treatment of chronic constipation syndromes.  Given the paucity of compounds proven safe 
and effective for colorectal cancer chemoprevention, this class of agent warrants further 
investigation.  Linaclotide is an FDA approved GUCY2C agonist formulated for immediate gastric 
release, with bioactivity in the small intestine.  It is approved for the treatment of irritable 
bowel syndrome with constipation and for chronic idiopathic constipation. The 
chemopreventive-relevant pharmacodynamic response of linaclotide in the human colon was 
not assessed during the agent’s development.  Here, we evaluated the effects of linaclotide in 
epithelial cells of the colorectum in healthy volunteers. 
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Materials and Methods 
Study Design 
The study was designed to test the hypothesis that orally administered linaclotide (Ironwood 
Pharmaceuticals, Inc., Cambridge, MA) engaged GUCY2C in the colorectum.  This study was 
important because the current formulation of linaclotide was designed to treat chronic 
constipation by releasing the bioactive peptide in the stomach’s acidic environment, which 
stimulates fluid secretion in the proximal small bowel.  In its current formulation, only ~1-3% of 
orally administered linaclotide or its active metabolite is recovered in stool.(16)  The present 
study examined whether sufficient concentrations of the orally administered peptide can 
successfully engage GUCY2C in epithelial cells of the colon and rectum, key targets for 
chemoprevention. The study comprised three stages (Fig. 1).  In Stage I, we evaluated the 
ability of a single oral daily dose of 0.87 mg of linaclotide administered for seven days to 
activate cGMP production in the colon and rectum sampled by colonoscopic biopsy following 
oral bowel preparation.  Stage II explored the ability of that same dose to activate rectal 
GUCY2C (the most distant site for chemoprevention) by sigmoidoscopy sampling following oral 
bowel preparation.  In Stage III, we explored the ability of linaclotide 0.87 mg to activate 
GUCY2C in rectal mucosa.  Biopsies were obtained by sigmoidoscopy following rectal 
preparation by tap water or PEG enema.  Stage III was designed to determine if the orally 
administered colonic bowel preparation affected the colonic distribution of linaclotide.  We 
anticipated that successful completion of these three stages would offer a dose reduction 
employing sigmoidoscopy and distal bowel cleansing by enema to identify the optimal dose of 
linaclotide for a subsequent chemoprevention trial. 
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The study was approved by the IRBs of the Mayo Clinic, Thomas Jefferson University, and Fox 
Chase Cancer Center and registered on ClinicalTrials.gov (NCT01950403).  The study population 
included healthy volunteers 18-65 years old, without personal or first degree family  history of 
CRC, inflammatory bowel disease or other recent (<3 months prior to day 0) or ongoing 
diseases producing acute or chronic diarrhea.  In Stage I, subjects received oral bowel 
preparation with 100 grams of polyethylene glycol 3350-electrolyte solution (PEG) (MoviPrep™, 
Salix Pharmaceuticals) followed by a screening colonoscopy.  Only subjects who tolerated the 
anesthesia and bowel preparation and who had no significant intestinal pathology were eligible 
to proceed to the intervention phase of the study (Fig. 1).  For the intervention phase, 
participants were randomly assigned to receive a single oral dose of either placebo or 
linaclotide 0.870 mg daily following an overnight fast for 7 consecutive days.  To assure 
compliance, subjects returned each day to the clinical research unit for witnessed dosing.  On 
day 7, participants received the second dose of MoviPrep at approximately 3:30 AM, and the 
final oral dose of linaclotide or placebo 2 h later.  Participants underwent the second 
colonoscopy 8 hours after the final linaclotide/placebo dose.  A total of 24 biopsies were taken 
from each participant during the screening and again during the post-intervention 
colonoscopies; 8 from each of the 3 anatomical locations including cecum, transverse colon, 
and rectum.  Three samples from each anatomical site were flattened immediately and fixed in 
pre-chilled paraformaldehyde (4%) overnight followed by standard tissue processing for 
analysis of Ki67.  The remaining five samples from each anatomical location were flash-frozen in 
liquid nitrogen and stored at -80°C for analysis of cGMP levels (2 samples) and VASP 
phosphorylation (3 samples).  In Stage II, screening and post-intervention flexible 
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sigmoidoscopy with 8 biopsies obtained from the rectum were performed, with all other 
parameters and study procedures (including oral MoviPrep) remaining the same.  In Stage III, 
only tap water or PEG enemas were used to cleanse the rectum.  Enemas were repeated (up to 
3 times) until clear of stool, before screening and post-intervention sigmoidoscopies were 
performed. 
Primary Endpoints 
The primary endpoint of the study was to identify a dose of linaclotide that produced a 60% 
response rate for the pharmacodynamic (PD) endpoint (cGMP level) based on rectal samples 
obtained at screening and post-intervention.  The pharmacological effect of linaclotide (or 
placebo) was calculated as the arithmetic difference in mean cGMP levels in biopsies from the 
colonoscopy before and after 7 days of intervention (linaclotide or placebo) in biopsies from the 
colonoscopy.  This represents the change in cGMP stimulated by 7 days of linaclotide in an 
individual subject.  The mean cGMP value was calculated based on 2 biopsies from the rectum 
assessed at each time point.  Each biopsy was analyzed in triplicate using a commercially 
available enzyme-linked immunosorbent assay (EIA) kit, so that each subject had 6 cGMP values 
at each time point. PD responses were calculated as difference in mean cGMP levels after 7 
days (the Pharmacological Effect) which is ≥ 0.94 times the baseline pooled intra-subject 
standard deviation (SD) of cGMP.  The intra-subject standard deviation (SD) was calculated 
based on the 6 cGMP values at baseline.  Cohort size calculations were based on mucosal cGMP 
data from studies with healthy volunteers (17, 18) and recommendations from a previous 
Phase 0 study design.(19)  This design yielded approximately 89% power to detect a 60% PD 
response rate at the subject level assuming a 1-sided alpha level of 0.05.(19) 
 10 
Cyclic GMP 
The primary endpoint for all stages was the ability of oral linaclotide to increase cGMP 
accumulation in colorectal mucosae.  The technique for cGMP quantification by immunoassay is 
well defined.(20)  At collection, mucosal biopsies were placed in cryogenic tubes, frozen in 
liquid nitrogen and archived in a -80°C freezer. For analysis, samples underwent 
cryopulverization before thawing in 500 μL of pre-cooled 5% trichloroacetic acid (TCA) followed 
by centrifugation (1,500 rpm, 10 min, 0-4°C).  Four hundred (400) μL of the supernatant was 
extracted with ether to remove TCA and then 250 μL was subjected to cGMP quantification 
using a validated enzyme-linked immunoassay (Cyclic GMP EIA Kit, Cayman Chemical Company, 
Ann Arbor, MI).  Tissue residues were dissolved in 0.2 N sodium hydroxide at 4°C overnight and 
protein concentrations determined by BCA protein assay kit (ThermoScientific, Rockford, IL). 
Cyclic GMP levels were normalized to the protein content from individual samples. 
Phosphorylation of VASP 
VASP phosphorylation from sites in the colon was quantified by immunoblot analyses of biopsy 
specimens from normal mucosa employing commercially available antibodies (Phospho-VASP 
(Ser239) Antibody, Cat: # 3114, Cell Signaling, Danvers, MA).  At least two biopsy specimens 
from each anatomical location were evaluated by two independent immunoblot analyses with 
quantification by densitometry and normalization to villin (VIL1), and the resulting 4 individual 
results averaged for comparisons. 
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Ki67 
The impact of linaclotide on cell proliferation index (number of proliferating cells) was 
quantified employing Ki67 immunohistochemistry (Monoclonal Mouse Anti-Human Ki-67 
Antigen, Clone MIB-1, Cat. #M7240, DAKO, Carpinteria, CA).  At least two biopsy specimens 
from each anatomical location were evaluated by enumerating Ki67-positive cells in 15 crypts, 
and the resulting individual crypt cell counts pooled for comparisons. 
Safety 
To confirm the safety and tolerability of linaclotide and placebo, all participants were 
monitored for toxicity from the time of their first dose of linaclotide/placebo. CTCAE version 4.0 
was used to summarize adverse events. 
Statistical Analyses 
Frequency tables and percentages summarized baseline and clinical characteristics, treatment 
data, and adverse event data, overall and by stage for each treatment arm.  Descriptive 
statistics, including mean, standard deviation, median, range, and frequencies (percentages), 
were used to summarize these data.  Fisher’s Exact and Wilcoxon Rank-Sum tests were used to 
test for associations between treatment arms and categorical and continuous data, 
respectively.  All statistical tests were 2-sided and performed using SAS version 9.4 (SAS 
Institute, Inc.).  Associations between treatment arms and secondary endpoints, including Ki67 
and VASP phosphorylation, were performed using student’s t test, using p<0.05 as the 
threshold for significance. 
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Results 
Subject Characteristics 
For this study, 46 subjects were screened, with 22 determined to be screen failures (Fig. 1).  The 
24 subjects enrolled had a mean age of 47.7 + 6.3 years, 79.2% were male, 45.8% were white, 
and 54.2% were black (Table 1).  Physical exams and laboratory studies revealed no clinically 
remarkable findings for this cohort of normal healthy volunteers (Supplementary Table 1). 
Subjects randomized to linaclotide and placebo groups had similar characteristics except for a 
slightly higher BMI in the linaclotide group (Supplementary Table 1).  Six subjects (5 placebo, 1 
linaclotide) had polyps >2 mm detected and removed at the pre-intervention colonoscopy 
(Supplementary Table 2): 3 were tubular adenomas (all received placebo) and 3 were 
hyperplastic polyps (1 received linaclotide, 2 received placebo). 
GUCY2C Activation 
Stage I 
In Stage I, 0.87 mg of oral linaclotide for 7 days produced pharmacological responses, increasing 
cGMP levels in epithelial cells of the cecum (Supplementary Table 3), transverse colon 
(Supplementary Table 4) and rectum (Supplementary Table 5) in two of three subjects receiving 
the active agent.  Pharmacological responses reflected PD responses in those two subjects in all 
anatomical sites, including the rectum (Supplementary Tables 3-5, Fig. 2).  PD responses in 
those two subjects were associated with clinical responses of increases in stool frequency and 
decreases in stool consistency on most days of dosing.  In contrast, the subject who received 
linaclotide but did not have cGMP PD responses also did not experience a change in bowel 
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movements.  Cyclic GMP responses were associated with increases in the phosphorylation of 
the downstream effector VASP in those subjects, but not in subjects who received placebo or in 
the one subject that received linaclotide but did not have a PD response (Fig. 3).  Similarly, 
cGMP PD responses to linaclotide were associated with reduced crypt proliferation in all 
anatomical segments, quantified by Ki67 immunohistochemistry (Fig. 4). 
Stage II 
PD responses in 2 of 3 actively treated subjects qualified as success, advancing the trial to Stage 
II (Fig. 1).  In this stage of the study, all procedures were identical to Stage I, including an oral 
bowel preparation, except pre- and post-intervention rectal biopsies were obtained by 
sigmoidoscopy (assessed only for cGMP levels).  As in stage I, 0.87 mg of oral linaclotide for 7 
days produced a PD response in 2 subjects, increasing cGMP levels in epithelial cells in the 
rectum (Fig. 5A) in two of three subjects receiving the active agent.  As before, PD responses in 
those two subjects were associated with an increase in stool frequency and a decrease in stool 
consistency while the subject who received linaclotide but did not have cGMP PD responses 
also did not experience a change in bowel movements.  Again, PD responses in 2 of 3 actively 
treated subjects qualified as success, advancing the trial to Stage III (Fig. 1). 
Stage III 
In this stage of the study, all procedures were identical to stage 2 except subjects received tap 
water enemas, rather than oral MoviPrep, prior to collection of pre- and post-intervention 
rectal biopsies by sigmoidoscopy and assessment of cGMP levels (Fig. 1).  Unlike Stages I and II, 
0.87 mg of oral linaclotide for 7 days did not produce a PD response in subjects receiving active 
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treatment (Fig. 5B).  Moreover, no subject in this group experienced a change in bowel 
movements with linaclotide administration.  As these results were unanticipated, we searched 
the research literature identifying one report suggesting that tap water enemas can disrupt the 
overlying epithelium sampled by endoscopic biopsy. In that context, changes in cGMP produced 
by linaclotide only occurred in epithelial cells, since they expressed the GUCY2C receptor.  In 
contrast to tap water, PEG enemas preserve epithelia by endoscopic biopsy.(21)  We amended 
the protocol so Stage III included a cohort that received a PEG enema instead of the tap water 
enema.  However, 0.87 mg of oral linaclotide for 7 days did not produce a PD response in 
subjects even following the PEG enema with MoviPrep (Fig. 5C).  The study was terminated 
because linaclotide failed to produce a PD response in at least two subjects in this cohort. 
Safety 
The dose of linaclotide employed here, 0.87 mg, was well tolerated and all subjects completed 
their full 7 days of dosing without discontinuation or dose reduction. Adverse events were all 
grade 1 by CTCAE criteria, and all subjects, linaclotide and placebo arms, experienced at least 1 
adverse event during the study. Adverse events were similar in both intervention cohorts, 
except for an increase in bowel frequency and a decrease in consistency, an expected effect of 
exposure to linaclotide (Supplementary Table 6).  Post-intervention endoscopy findings were 
similar in the linaclotide and placebo groups (Supplementary Table 7). 
Discussion 
In health, GUCY2C plays a key regulatory role in proliferative and metabolic processes that 
oppose tumorigenesis.  However, the near universal over-expression of GUCY2C in human 
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colorectal cancers, coupled with the loss of endogenous ligands (guanylin and uroguanylin), 
highlight a potential targeted prevention strategy for colorectal cancer involving oral 
replacement therapy.  This presumes that during colorectal carcinogenesis, GUCY2C is a 
dormant tumor-suppressing receptor whose re-engagement by exogenous ligand rescues 
dysregulated cell growth.  In that context, GUCY2C signaling inhibits the cell cycle of normal 
human intestinal cells and human colon carcinoma cells in vitro and ex vivo.(7, 8, 22)  Similarly, 
GUCY2C signaling reverses the tumorigenic metabolic phenotype in human colon cancer 
cells.(7, 8)  Further, mice on oral uroguanylin demonstrated a decrease in small and large 
intestine adenoma formation compared to controls. Moreover, hormone loss silencing GUCY2C 
appears to be required for tumorigenesis since transgenic expression of guanylin, which cannot 
be suppressed, eliminates carcinogen-induced colorectal tumorigenesis in mice.(14) 
Linaclotide, a chemically synthesized 14-amino acid peptide composed of naturally occurring L-
amino acids, shares over 60% amino acid identity with guanylin and uroguanylin.  This drug is 
approved by FDA to treat constipation-predominant irritable bowel syndrome (IBS-C) and 
chronic idiopathic constipation (CIC) under the trade name Linzess™.(23, 24)  Linaclotide 
enhances bowel function by activating GUCY2C and inducing fluid and electrolyte secretion in 
the small intestine, improving frequency and stool consistency.  Generally, linaclotide is well 
tolerated, with side effects primarily reflecting on-target activity of GUCY2C mediating fluid and 
electrolyte secretion underlying diarrhea.(23, 24)  The robust safety of this agent is underscored 
by the negligible bioavailability of orally administered linaclotide.(16, 25)  While treatment of 
chronic constipation syndromes usually involves daily oral linaclotide doses of 0.145 or 0.290 
mg,(23, 24) daily doses up to 1 mg are safe. Here, a dose of 0.87 mg was selected because the 
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primary goal was to determine whether linaclotide activated GUCY2C signaling in the distal 
rectum, a site that is exposed only to ~1-3% of the oral dose likely reflecting proteolysis.(16, 25) 
 A maximum oral dose of linaclotide (0.87 mg) administered for 7 days increased cGMP, 
associated with changes in VASP phosphorylation and Ki67 staining, in biopsy specimens from 
the cecum, transverse colon, and rectum, obtained by colonoscopy following bowel preparation 
by oral MoviPrep administration in some healthy volunteers (Stage I).  Similarly, 0.87 mg of oral 
linaclotide for 7 days increased cGMP accumulation in epithelial cells of the rectum recovered 
by sigmoidoscopy following oral MoviPrep bowel preparation in some healthy volunteers (Stage 
II).  In each of these cohorts, changes in cGMP were associated with changes in frequency 
and/or stool consistency induced by linaclotide.  Conversely, subjects administered linaclotide 
that did not experience changes in bowel movements did not exhibit changes in mucosal cGMP.  
Importantly, linaclotide failed to increase rectal mucosa cGMP in subjects in which rectal stool 
was cleared by enema (Stage III), in the absence of oral MoviPrep. 
We can only speculate about mechanisms that prevented linaclotide from activating rectal 
cGMP production in Stage III. First, it is noteworthy that no subject in Stage III experienced 
changes in bowel movements with linaclotide.  Previous clinical studies revealed that ~20-30% 
of patients did not experience changes in bowel movements when administered linaclotide.(26)  
This variability in response could reflect genetic factors affecting the pharmacodynamics of 
linaclotide in epithelial cells in some individuals. In that context, GUCY2C expression in normal 
epithelia varies about 2 orders of magnitude in the population.(27)  Further, mutations that 
alter GUCY2C activity have been described.(28-31)  Alternatively, these differences may relate 
to pharmacokinetic polymorphisms, with differences in metabolic clearance of the peptide in 
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the intestine limiting the availability of active drug in some patients.  Moreover, the 
contribution of environmental factors extrinsic to epithelial cells, for example variations in the 
microbiome, might contribute to the variability in individual responses to linaclotide. These 
possibilities remain to be explored. 
Additionally, the inactivity of linaclotide in Stage III could reflect the bowel preparation 
employed on the last day of dosing—a laxative preparation effect.  In Stages I and II, subjects 
received an oral dose of MoviPrep to clear stool from the colorectum prior to the last dose of 
linaclotide and endoscopy.  In both of these first two stages, linaclotide elevated cGMP in rectal 
mucosa I some subjects. However, in the absence of oral MoviPrep before the last dose of drug, 
linaclotide was ineffective in elevating cGMP in rectal mucosa. It is tempting to speculate that 
changes in cGMP, and downstream effectors, in mucosa from the colorectum observed in Stage 
I and II reflected only the last dose of linaclotide.  Indeed, GUCY2C interactions with ligands 
occur with rapid on-off kinetics, and cGMP production reflects receptor occupancy, without 
persistence following ligand dissociation. In that context, oral MoviPrep may have cleared stool 
and increased intestinal transit, delivering a greater quantity of linaclotide more rapidly to the 
colorectum in Stages I and II. Alternatively, the presence of stool throughout the colorectum on 
day 7 may have prevented delivery of active linaclotide to the colorectal mucosa, possibly 
reflecting the established surface-active characteristics of GUCY2C ligands and the resulting 
immobilization of linaclotide in the solid phase of the intestinal contents.  Again, these 
possibilities remain to be explored. 
These observations suggest concrete steps for advancing GUCY2C as a target for colorectal 
cancer chemoprevention by oral hormone replacement therapy. For example, future studies 
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should identify subjects who are biological responders to linaclotide, to avoid enrolling subjects 
who are insensitive to this agent because of pharmacokinetic or pharmacodynamic differences. 
Further, it would be useful to understand the molecular mechanisms underlying insensitivity to 
GUCY2C ligands in the population to better generalize the ultimate chemoprevention strategy 
to the greatest number of patients.  Moreover, it will be important to test sustained release 
formulations of linaclotide that are targeted to the colorectum, to maximize pharmacodynamic 
effects of GUCY2C activation and downstream signaling mediating chemoprevention. 
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Table 1. Baseline Demographics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Linaclotide                                        
(N=12) 
Placebo                       
(N=12) 
Total                                       
(N=24) p value 
 Gender       0.321 
    Female 4 (33.3%) 1 (8.3%) 5 (20.8%)   
    Male 8 (66.7%) 11 (91.7%) 19 (79.2%)   
          
 Age       1.002 
    N 12 12 24   
    Mean (SD) 47.9 (5.8) 47.5 (7.0) 47.7 (6.3)   
    Median 48.0 49.5 48.0   
    Q1, Q3 45.0, 51.5 44.0, 52.0 45.0, 51.5   
    Range (35.0-58.0) (35.0-57.0) (35.0-58.0)   
          
 Race       1.001 
    White 6 (50.0%) 5 (41.7%) 11 (45.8%)   
    Black or African 
 American 
6 (50.0%) 7 (58.3%) 13 (54.2%)   
          
 Ethnicity       0.481 
    Hispanic or Latino 0 (0.0%) 2 (16.7%) 2 (8.3%)   
    Non-Hispanic 12 (100.0%) 10 (83.3%) 22 (91.7%)   
 
1Fisher Exact    2Wilcoxon 
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Figure Legends 
Figure 1. CONSORT flow diagram of subject progress through the phases of the clinical trial. 
Figure 2. Cyclic GMP pharmacodynamic response to linaclotide or placebo in healthy 
volunteers in Stage I. Cyclic GMP pharmacodynamic response was calculated as described in 
Methods. C, cecum; TC, transverse colon, R, rectum. 
Figure 3. VASP phosphorylation in mucosal biopsies from healthy subjects treated with 
linaclotide or placebo in Stage I. Phosphorylated VASP was quantified by densitometry 
following immunoblot analysis of biopsies from the cecum, transverse colon, and rectum. The 
amount of phosphorylated VASP was normalized to the epithelial marker villin. For each 
intestinal segment, the ratio of normalized phosphorylated villin on day 1 (pre-dose) and 7 
(post-dose) were calculated. *, p<0.05. 
Figure 4. Cell proliferation in crypts in mucosal biopsies from healthy subjects treated with 
linaclotide or placebo in Stage I. Proliferation was quantified by enumerating cells expressing 
Ki67 by immunofluorescence. Ki67 was enumerated in 10-20 crypts in each biopsy and means 
were calculated. For each intestinal segment, the ratio of mean Ki67 expression on day 1 (pre-
dose) and 7 (post-dose) were calculated. C, cecum; TC, transverse colon, R, rectum. ***, 
p<0.001. 
Figure 5. Cyclic GMP pharmacodynamic response to linaclotide or placebo in healthy 
volunteers in Stage II and III. Cyclic GMP pharmacodynamic response was calculated as 
described in Methods in rectal biopsies of healthy subjects in (A) Stage II, (B) Stage III following 
tap water enemas, and (C) Stage III following PEG enemas. 
